ECONOMIC-ANALYSIS OF PROPHYLACTIC G-CSF AFTER MINI-BEAM SALVAGE CHEMOTHERAPY FOR HODGKINS AND NON-HODGKINS-LYMPHOMA

被引：18

作者：

DRANITSARIS, G ^{[1
]}

SUTCLIFFE, SB ^{[1
]}

机构：

[1] PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT PHARM,TORONTO,ON M4X 1K9,CANADA

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 17卷 / 1-2期

关键词：

COST; G-CSF; MINI-BEAM; FEBRILE NEUTROPENIA; LYMPHOMA;

D O I：

10.3109/10428199509051714

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The objectives of this study were to compare the costs of managing lymphoma patients who underwent mini-BEAM salvage chemotherapy with G-CSF prophylactic support against a group of similar patients without growth factors. Methods used included: 1) A retrospective chart review was conducted to estimate the average length of hospitalization and resource consumption for the management of fever and neutropenia in the two groups of patients and 2) An economic analysis was then performed from a hospital perspective which considered only institutional resource utilization. Costs of antibiotic support and monitoring, lab tests as well as G-CSF were calculated. Results demonstrated that overall, patients who received prophylactic G-CSF after chemotherapy required 2 fewer hospital days compared to controls. The administration of G-CSF resulted in a savings of approximately $1580/patient relative to control. When the initial G-CSF expenditure was included in the analysis, the total net cost/patient was similar between the two groups. In conclusion, the results of the current study support the routine use of G-CSF in patients receiving salvage chemotherapy with mini-BEAM. The initial G-CSF expenditure would be offset by reduced hospitalization.

引用

页码：139 / 145

页数：7

共 17 条

[1]

Pizzo P.A., Empiric therapy and prevention of infection in the immunocompromised host, Principles and practice of infectious diseases, 3rd ed, pp. 2303-2311, (1990)

[2]

Schimpff S.C., Young V.M., Greene W.H., Vermeulen G.D., Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens, Ann. Int. Med. Jl. lian-llU., (1972)

[3]

Hellman S., Principles of radiation therapy, Cancer: Principles and practice of oncology, 4th ed, pp. 248-279, (1989)

[4]

Schimpff S.C., Infections in the compromised host, Principles and practice of infectious diseases, 3rd ed, pp. 2258-2265, (1990)

[5]

Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J., Qualitative relationship between circulating leukocytes and infection in patients with acute leukemia, Ann. Int. Med., 64, pp. 328-340, (1966)

[6]

Hollingshead L.M., Goa K.L., Recombinant granulocyte colony-stimulating factor (rG-CSF): A review of its pharmacological properties and prospective role in neutropenic conditions, Drugs, 42, pp. 300-330, (1991)

[7]

Herrmann F., Schulz G., Wieser M., Kolbe K., Nicolay U., Noack M., Lindemann A., Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy, Am. J. Med., 88, pp. 619-624, (1990)

[8]

Nemunaitis J., Rabinowe S.N., Singer J.W., Bierman P.J., Vose J.M., Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer, N. Eng. J. Med., 324, pp. 1773-1778, (1991)

[9]

Gabrilove J.L., Jakubowski A., Scher H., Sternberg C., Wong G., Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium, N. Eng. J. Med., 318, pp. 1414-1422, (1988)

[10]

Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N. Eng. J. Med, 325, pp. 164-170, (1991)

← 1 2 →